Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783701 | 0.86 | ALDH1A1 (0.38) | CYP2C19MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL5782618 | 0.78 | LMNA (0.36) | CYP2C19MAPTKMT2AMEN1LMNA | |
| SCHEMBL5782151 | 0.74 | MAPT (0.47) | CYP2C19MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL7823572 | 0.73 | MAPT (0.50) | CYP2C19MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL5781907 | 0.72 | TDP2 (0.45) | CYP2C19MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL9695796 | 0.69 | TDP2 (0.38) | CYP2C19MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL5780859 | 0.69 | ALDH1A1 (0.43) | CYP2C19MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL9568083 | 0.68 | MAPT (0.50) | MAPTALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL30398320 | 0.68 | MAPT (0.50) | MAPTALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL8759432 | 0.66 | TSHR (0.49) | MAPTKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436293-B1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-6946472-B2 | Polycyclic compounds exhibiting anti-tumor activities | HOFFMAN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1436293-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6680326-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-11 | — | — | US | disclosed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073691-A1 | Polycyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 | CYP2C19 1432/4885MAPT 4594/4885KDM4E 1718/4885 |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | RB1, CCNA1, ACIN1 | CYP2C19 2154/4885MAPT 4854/4885KDM4E 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.